Skip to content
Well Researched

CJC-1295 (without DAC)

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH).

Also known as: Short-Acting Growth Hormone Releasing Hormone Analog, Modified GRF 1-29, without DAC

Typical Dose 100mcg
Storage Refrigerate reconstituted; store lyophilized powder away from light
How Often 2x daily (morning and bedtime)

Overview

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body's natural GH secretion patterns. Unlike its DAC-modified counterpart, this version has a brief half-life of approximately 30 minutes, allowing for more precise control over growth hormone pulses and reduced risk of receptor desensitization.

Key Benefits

  • Natural GH Pulse Restoration
  • IGF-1 Elevation
  • Pituitary Function Support

Preserves natural GH pulsatility, minimal side effects, no receptor desensitization, precise control over GH release

Mechanism of Action

Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses

Pharmacokinetics

Peak plasma concentration: 15 min. Elimination half-life: 30 min. Largely cleared by: ~2.5 hrs.

Research Protocols Injectable

GoalDoseFrequencyRoute
Anti-Aging/Wellness100mcg2x daily (morning and bedtime)Subcutaneous
Body Composition100-150mcg3x daily (morning, post-workout, bedtime)Subcutaneous
Maximum GH Release200mcg2-3x daily with GHRPSubcutaneous
Sleep Enhancement100-200mcgOnce at bedtimeSubcutaneous

Research protocols from published literature — not dosing recommendations.

Peptide Interactions

  • Ipamorelin — Synergistic: Excellent combination - Ipamorelin (GHRP) + CJC-1295 (GHRH) provides complementary GH release through different receptor pathways
  • GHRP-6 — Synergistic: Strong synergy when combined - GHRP-6 amplifies the GH pulse initiated by CJC-1295
  • GHRP-2 — Synergistic: Potent combination for maximizing growth hormone release through dual pathway activation
  • Hexarelin — Monitor Combination: Can be combined but monitor for excessive GH elevation due to Hexarelin's potency
  • CJC-1295 with DAC — Avoid Combination: Never combine different CJC-1295 variants - choose based on desired release pattern
  • Tesamorelin — Use Caution: Both bind to pituitary GHRH receptors. Combining saturates receptors without amplifying GH release, risking receptor desensitization and blunted pulsatility. Choose one based on your protocol goals.
  • MK-677 — Compatible: Different mechanisms - MK-677 provides continuous ghrelin stimulation while CJC-1295 offers pulsatile GHRH

Peptide Instructions Injectable

Supplies:

  • Bacteriostatic water (BAC water)
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  • CJC-1295 (without DAC) lyophilized powder vial

How to Reconstitute Injectable

  1. 1Allow vial to reach room temperature (15-20 minutes)
  2. 2Clean vial top with alcohol swab and allow to dry
  3. 3Calculate required bacteriostatic water volume using the calculator below
  4. 4Draw calculated volume of bacteriostatic water into syringe
  5. 5Inject water slowly down the inside wall of the vial (never directly onto powder)
  6. 6Gently swirl until powder completely dissolves (never shake)
  7. 7Solution should be clear - discard if cloudy or contains particles
  8. 8Store reconstituted solution in refrigerator at 2-8°C

What to Expect Injectable

Day 1-7: Improved sleep quality, vivid dreams common due to enhanced REM sleep. Week 2-4: Increased recovery from workouts, reduced DOMS, better pumps. Week 4-8: Noticeable improvements in skin quality, minor body composition changes. Week 8-12: More significant lean mass gains, fat loss, improved joint comfort. Week 12+: Continued gradual improvements in body composition and well-being.

Side Effects & Safety

Generally well-tolerated with minimal side effects at recommended doses. May cause temporary facial flushing or warmth for 5-10 minutes post-injection. Monitor blood glucose if diabetic - GH can affect insulin sensitivity. Not recommended for those with active cancer due to growth-promoting effects. Avoid if you have diabetic retinopathy or severe kidney disease.

Generally well-tolerated with minimal side effects at recommended doses. May cause temporary facial flushing or warmth for 5-10 minutes post-injection. Monitor blood glucose if diabetic - GH can affect insulin sensitivity. Not recommended for those with active cancer due to growth-promoting effects. Avoid if you have diabetic retinopathy or severe kidney disease.

Community Insights

CJC-1295 (without DAC) should be stored at Refrigerate immediately, use within 30 days of reconstitution.

Molecular Information

Molecular Weight 3,367.97 Da
Length 30
Type GHRH analog (Mod GRF 1-29)
Sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

References

  1. Long-term Safety Profile of Modified GRF Analogs (2015) · 2015
  2. Growth Hormone Pulsatility with Mod GRF 1-29 (2008) · 2008
  3. Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006) · 2006
  4. Comparative Analysis: CJC-1295 vs Native GHRH (2010) · 1295

Research reference only. Not medical advice.